Alle verbonden artikelen

A prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancer.

Auteurs : Gil T, Aoun F, Cabri P, Maisonobe P, Van Velthoven R
Jaar : 2015
Journal : Ther Adv Urol
Volume : 7(3)
Pagina's : 116-24

Retrospective Rescreening of Negative Cervical Cytology Samples Preceding Histologically Proven CIN2-3 and Squamous Cell Carcinoma: An Educational Opportunity to Understand and Prevent Laboratory Errors.

Auteurs : Feoli F, Renard C, Abouyahia M, de Wind R, Larsimont D, Arbyn M
Jaar : 2015
Journal : Acta Cytol.
Volume : 59(3)
Pagina's : 265-72

Facteurs pronostiques et cancers bronchopulmonaires

Auteurs : Berghmans T
Jaar : 2015
Journal : Rev Mal Respir
Volume : 7(4)
Pagina's : 322-30

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.

Auteurs : Perez EA, Awada A, OShaughnessy J, Rugo HS, Twelves C, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J
Jaar : 2015
Journal : Lancet Oncol
Volume : 16
Pagina's : 1556-68

Radioembolisation and portal vein embolization before resection of large hepatocellular carcinoma.

Auteurs : Bouazza F, Poncelet A, Garcia CA, Delatte P, Engelholm JL, Gomez Galdon M, Deleporte A, Hendlisz A, Vanderlinden B, Flamen P, Donckier V
Jaar : 2015
Journal : World J Gastroenterol
Volume : 21
Pagina's : 9666-70

High-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombination.

Auteurs : Sijmons S, Thys K, Mbong Ngwese M, Van Damme E, Dvorak J, Van Loock M, Li G, Tachezy R, Busson L, Aerssens J, Van Ranst M, Maes P
Jaar : 2015
Journal : J. Virol.
Volume : null(null)
Pagina's : pii: JVI.00578-15

Opposite prognostic significance of cellular and serum circulating microRNA-150 in Chronic Lymphocytic Leukemia patients.

Auteurs : Stamatopoulos B, Van Damme M, Crompot E, Dessars B, El Housni H, Mineur P, Meuleman N, Bron D, Lagneaux L
Jaar : 2015
Journal : Mol. Med.
Volume : 21(1)
Pagina's : 123-33

'New' metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy, Breast Cancer Research 2015, 17: 150

Auteurs : Twelves C, Cortes J, Kaufman PA, Yelle L, Awada A, Binder T, Olivo M, O Shaughnessy J, Jove M, Perez EA
Jaar : 2015
Journal : Breast Cancer Res
Volume : 17
Pagina's : 150

Acute respiratory failure in patients with hematological malignancies: outcomes according to initial ventilation strategy. A groupe de recherche respiratoire en réanimation onco-hématologique (Grrr-OH) study.

Auteurs : Lemiale V, Resche-Rigon M, Mokart D, Pène F, Rabbat A, Kouatchet A, Vincent F, Bruneel F, Nyunga M, Lebert C, Perez P, Meert AP, Benoit D, Chevret S, Azoulay E
Jaar : 2015
Journal : Ann Intensive Care
Volume : 5
Pagina's : 28

Vulvar metastasis from bladder cancer.

Auteurs : Aoun F, El Rassy E, Kourie HR, Hawaux E, Van Velthoven R
Jaar : 2015
Journal : Case Rep Obstet Gynecol
Volume : 2015
Pagina's : 324634

Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma.

Auteurs : Czuczman MS, Kahanic S, Forero A, Davis G, Munteanu M, Van Den Neste E, Offner F, Bron D, Quick D, Fowler N
Jaar : 2015
Journal : Ann Hematol
Volume : 94(4)
Pagina's : 633-41

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.

Auteurs : Sonnenblick A, Brohée S, Fumagalli D, Vincent D, Venet D, Ignatiadis M, Salgado R, Van den Eynden G, Rothé F, Desmedt C, Neven P, Loibl S, Denkert C, Joensuu H, Loi S, Sirtaine N, Kellokumpu-Lehtinen PL, Piccart-Gebhart M, Sotiriou C
Jaar : 2015
Journal : BMC Med
Volume : 13(1)
Pagina's : 177

Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal.

Auteurs : Zagouri F, Liakou P, Bartsch R, Peccatori FA, Tsigginou A, Dimitrakakis C, Zografos GC, Dimopoulos MA, Azim HA
Jaar : 2015
Journal : Breast
Volume : 24(4)
Pagina's : 513-23

Thrombo-embolic events in cancer patients with impaired renal function

Auteurs : Elalamy I, Canon JL, Bols A, Lybaert W, Duck L, Jochmans K, Bosquée L, Peeters M, Awada A, Clement P, Holbrechts S, Baurain JF, Mebis J, Nortier J
Jaar : 2015
Journal : Belgian J Medical Oncology
Volume : 9(2)
Pagina's : 53-60

Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).

Auteurs : de Witte T, Suciu S, Meert L, Halkes C, Selleslag D, Bron D, Amadori S, Willemze R, Muus P, Baron F
Jaar : 2015
Journal : Ann Hematol
Volume : 94
Pagina's : 1981-9

Evolving paradigms in multifocal breast cancer.

Auteurs : Salgado R, Aftimos P, Sotiriou C, Desmedt C
Jaar : 2015
Journal : Semin. Cancer Biol.
Volume : 31C
Pagina's : 111-118

Prophylaxis of febrile neutropenia in adults receiving chemotherapy needs to be adapted to the risk.

Auteurs : Georgala A, Klastersky J
Jaar : 2015
Journal : Expert Rev Hematol
Volume : 8(1)
Pagina's : 115-21

Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.

Auteurs : Nuciforo PG, Aura C, Holmes E, Prudkin L, Jimenez J, Martinez P, Ameels H, de la Peña L, Ellis C, Eidtmann H, Piccart-Gebhart M, Scaltriti M, Baselga J
Jaar : 2015
Journal : Ann Oncol
Volume : 26
Pagina's : 1494-500

Has the time come for genomic tests to guide the use of adjuvant chemotherapy in node-positive breast cancer?

Auteurs : Azim HA
Jaar : 2015
Journal : Ann Oncol
Volume : 26(8)
Pagina's : 1521-3

Enabling semantic interoperability in multi-centric clinical trials on breast cancer.

Auteurs : Alonso-Calvo R, Perez-Rey D, Paraiso-Medina S, Claerhout B, Hennebert P, Bucur A
Jaar : 2015
Journal : Comput Methods Programs Biomed
Volume : 118(3)
Pagina's : 322-329